Skip to main content
Top
Published in: Current Treatment Options in Gastroenterology 3/2015

01-09-2015 | Pancreas (T Stevens, Section Editor)

Drug Therapy for Acute Pancreatitis

Authors: Yan Bi, MD, PhD, Tegpal Atwal, MD, Santhi Swaroop Vege, MD

Published in: Current Treatment Options in Gastroenterology | Issue 3/2015

Login to get access

Opinion Statement

Acute pancreatitis (AP) remains a disease with significant morbidity and mortality, and the reported incidence is increasing. Despite a significant amount of research over the last few decades with greater understanding of the pathophysiology of AP, there are still no specific drugs available. Therefore, the current treatment is limited to supportive care such as fluid, nutrition, and treatment of complications. In this review, we discuss potential novel targeted pharmacologic approaches that may offer promise in the treatment of AP such as anti-secretory agents, protease inhibitors, probiotics, anti-inflammatory agents, anti-oxidants, and anti-TNF-α agents. While many drugs were reported to have efficacy in animal experiments, human studies have been largely disappointing. Better understanding of AP pathophysiology likely will facilitate future therapies in AP.
Literature
1.•
go back to reference Peery AF, Dellon ES, Lund J, Crockett SD, McGowan CE, Bulsiewicz WJ, Gangarosa LM, Thiny MT, Stizenberg K, Morgan DR, Ringel Y et al.: Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology (2012) 143(5):1179–1187 e1171-1173. Updated information on financial burdens of common GI diseases including acute pancreatitis in the USA.PubMedPubMedCentral Peery AF, Dellon ES, Lund J, Crockett SD, McGowan CE, Bulsiewicz WJ, Gangarosa LM, Thiny MT, Stizenberg K, Morgan DR, Ringel Y et al.: Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology (2012) 143(5):1179–1187 e1171-1173. Updated information on financial burdens of common GI diseases including acute pancreatitis in the USA.PubMedPubMedCentral
2.
go back to reference Banks PA, Freeman ML. Practice guidelines in acute pancreatitis. Am J Gastroenterol. 2006;101(10):2379–400.PubMed Banks PA, Freeman ML. Practice guidelines in acute pancreatitis. Am J Gastroenterol. 2006;101(10):2379–400.PubMed
3.•
go back to reference Tenner S, Baillie J, DeWitt J, Vege SS: American college of gastroenterology guideline: Management of acute pancreatitis. Am J Gastroenterol (2013) 108(9):1400–1415; 1416. Most recent treatment guideline from ACG for acute pancreatitis.PubMed Tenner S, Baillie J, DeWitt J, Vege SS: American college of gastroenterology guideline: Management of acute pancreatitis. Am J Gastroenterol (2013) 108(9):1400–1415; 1416. Most recent treatment guideline from ACG for acute pancreatitis.PubMed
5.
go back to reference Singh S, Bhardwaj U, Verma SK, Bhalla A, Gill K. Hyperamylasemia and acute pancreatitis following anticholinesterase poisoning. Hum Exp Toxicol. 2007;26(6):467–71.PubMed Singh S, Bhardwaj U, Verma SK, Bhalla A, Gill K. Hyperamylasemia and acute pancreatitis following anticholinesterase poisoning. Hum Exp Toxicol. 2007;26(6):467–71.PubMed
6.
go back to reference Dyck WP, Texter Jr EC, Lasater JM, Hightower Jr NC. Influence of glucagon on pancreatic exocrine secretion in man. Gastroenterology. 1970;58(4):532–9.PubMed Dyck WP, Texter Jr EC, Lasater JM, Hightower Jr NC. Influence of glucagon on pancreatic exocrine secretion in man. Gastroenterology. 1970;58(4):532–9.PubMed
7.
go back to reference Fontana G, Costa PL, Tessari R, Labo G. Effect of glucagon on pure human exocrine pancretic secretion. Am J Gastroenterol. 1975;63(6):490–4.PubMed Fontana G, Costa PL, Tessari R, Labo G. Effect of glucagon on pure human exocrine pancretic secretion. Am J Gastroenterol. 1975;63(6):490–4.PubMed
8.
go back to reference Jensen HE. The effect of glucagon on pressure and oxygen saturation of splanchnic venous blood. Am J Dig Dis. 1966;11(6):447–52.PubMed Jensen HE. The effect of glucagon on pressure and oxygen saturation of splanchnic venous blood. Am J Dig Dis. 1966;11(6):447–52.PubMed
9.
go back to reference Condon RE, Woods JH, Poulin TL, Wagner WG, Pissiotis CA. Experimental pancreatitis treated with glucagon or lactated ringer solution. Arch Surg. 1974;109(2):154–8.PubMed Condon RE, Woods JH, Poulin TL, Wagner WG, Pissiotis CA. Experimental pancreatitis treated with glucagon or lactated ringer solution. Arch Surg. 1974;109(2):154–8.PubMed
10.
go back to reference Waterworth MW, Barbezat GO, Hickman R, Terblanche J. A controlled trial of glucagon in experimental pancreatitis. Br J Surg. 1976;63(8):617–20.PubMed Waterworth MW, Barbezat GO, Hickman R, Terblanche J. A controlled trial of glucagon in experimental pancreatitis. Br J Surg. 1976;63(8):617–20.PubMed
11.
go back to reference Papp M, Ribet A, Fodor I, Nemeth PE, Feher S, Horvath JE, et al. Glucagon treatment of experimental acute pancreatitis. Acta Med Acad Sci Hung. 1975;32(2):105–16.PubMed Papp M, Ribet A, Fodor I, Nemeth PE, Feher S, Horvath JE, et al. Glucagon treatment of experimental acute pancreatitis. Acta Med Acad Sci Hung. 1975;32(2):105–16.PubMed
12.
go back to reference Durr HK, Weihe W, Bode C, Bode JC. A controlled trial of glucagon in acute experimental pancreatitis in rats. Z Gastroenterol. 1977;15(12):728–33.PubMed Durr HK, Weihe W, Bode C, Bode JC. A controlled trial of glucagon in acute experimental pancreatitis in rats. Z Gastroenterol. 1977;15(12):728–33.PubMed
13.
go back to reference Knight MJ, Condon JR, Smith R. Possible use of glucagon in the treatment of pancreatitis. Br Med J. 1971;2(5759):440–2.PubMedPubMedCentral Knight MJ, Condon JR, Smith R. Possible use of glucagon in the treatment of pancreatitis. Br Med J. 1971;2(5759):440–2.PubMedPubMedCentral
14.
go back to reference Waterworth MW, Barbezat GO, Bank S. Letter: glucagon in treatment of acute pancreatitis. Lancet. 1974;1(7868):1231.PubMed Waterworth MW, Barbezat GO, Bank S. Letter: glucagon in treatment of acute pancreatitis. Lancet. 1974;1(7868):1231.PubMed
15.
go back to reference Condon JR, Knight M, Day JL. Glucagon therapy in acute pancreatitis. Br J Surg. 1973;60(7):509–11.PubMed Condon JR, Knight M, Day JL. Glucagon therapy in acute pancreatitis. Br J Surg. 1973;60(7):509–11.PubMed
16.
go back to reference Fleischer K, Kasper H. Glucagon therapy of pancreatitis. Verh Dtsch Ges Inn Med. 1973;79:870–3.PubMed Fleischer K, Kasper H. Glucagon therapy of pancreatitis. Verh Dtsch Ges Inn Med. 1973;79:870–3.PubMed
17.
go back to reference Durr HK, Maroske D, Zelder O, Bode JC. Glucagon therapy in acute pancreatitis. Report of a double-blind trial. Gut. 1978;19(3):175–9.PubMedPubMedCentral Durr HK, Maroske D, Zelder O, Bode JC. Glucagon therapy in acute pancreatitis. Report of a double-blind trial. Gut. 1978;19(3):175–9.PubMedPubMedCentral
18.
go back to reference Debas HT, Hancock RJ, Soon-Shiong P, Smythe HA, Cassim MM. Glucagon therapy in acute pancreatitis: prospective randomized double-blind study. Can J Surg. 1980;23(6):578–80.PubMed Debas HT, Hancock RJ, Soon-Shiong P, Smythe HA, Cassim MM. Glucagon therapy in acute pancreatitis: prospective randomized double-blind study. Can J Surg. 1980;23(6):578–80.PubMed
19.
go back to reference Kronborg O, Bulow S, Joergensen PM, Svendsen LB. A randomized double-blind trial of glucagon in treatment of first attack of severe acute pancreatitis without associated biliary disease. Am J Gastroenterol. 1980;73(5):423–5.PubMed Kronborg O, Bulow S, Joergensen PM, Svendsen LB. A randomized double-blind trial of glucagon in treatment of first attack of severe acute pancreatitis without associated biliary disease. Am J Gastroenterol. 1980;73(5):423–5.PubMed
20.
go back to reference Hotz J, Goebell H, Ziegler R. Calcitonin and exocrine pancreatic secretion in man: inhibition of enzymes stimulated by CCK-pancreozymin, caerulein, or calcium—no response to vagal stimulation. Gut. 1977;18(8):615–22.PubMedPubMedCentral Hotz J, Goebell H, Ziegler R. Calcitonin and exocrine pancreatic secretion in man: inhibition of enzymes stimulated by CCK-pancreozymin, caerulein, or calcium—no response to vagal stimulation. Gut. 1977;18(8):615–22.PubMedPubMedCentral
21.
go back to reference Goebell H, Ammann R, Herfarth C, Horn J, Hotz J, Knoblauch M, et al. A double-blind trial of synthetic salmon calcitonin in the treatment of acute pancreatitis. Scand J Gastroenterol. 1979;14(7):881–9.PubMed Goebell H, Ammann R, Herfarth C, Horn J, Hotz J, Knoblauch M, et al. A double-blind trial of synthetic salmon calcitonin in the treatment of acute pancreatitis. Scand J Gastroenterol. 1979;14(7):881–9.PubMed
22.
go back to reference Li J, Wang R, Tang C. Somatostatin and octreotide on the treatment of acute pancreatitis—basic and clinical studies for three decades. Curr Pharm Des. 2011;17(16):1594–601.PubMed Li J, Wang R, Tang C. Somatostatin and octreotide on the treatment of acute pancreatitis—basic and clinical studies for three decades. Curr Pharm Des. 2011;17(16):1594–601.PubMed
23.
go back to reference Lankisch PG, Koop H, Winckler K, Folsch UR, Creutzfeldt W. Somatostatin therapy of acute experimental pancreatitis. Gut. 1977;18(9):713–6.PubMedPubMedCentral Lankisch PG, Koop H, Winckler K, Folsch UR, Creutzfeldt W. Somatostatin therapy of acute experimental pancreatitis. Gut. 1977;18(9):713–6.PubMedPubMedCentral
24.
go back to reference Usadel KH, Leuschner U, Uberla KK. Treatment of acute pancreatitis with somatostatin: a multicenter double blind study. N Engl J Med. 1980;303(17):999–1000.PubMed Usadel KH, Leuschner U, Uberla KK. Treatment of acute pancreatitis with somatostatin: a multicenter double blind study. N Engl J Med. 1980;303(17):999–1000.PubMed
25.
go back to reference Limberg B, Kommerell B. Treatment of acute pancreatitis with somatostatin. N Engl J Med. 1980;303(5):284.PubMed Limberg B, Kommerell B. Treatment of acute pancreatitis with somatostatin. N Engl J Med. 1980;303(5):284.PubMed
26.
go back to reference Karatapanis SGS, Kassl E, Zafiris I, Filis H, Artikis V. Octreotide in the treatment of acute pancreatitis. Gut. 1995;37:A186. Karatapanis SGS, Kassl E, Zafiris I, Filis H, Artikis V. Octreotide in the treatment of acute pancreatitis. Gut. 1995;37:A186.
27.
go back to reference Choi TK, Mok F, Zhan WH, Fan ST, Lai EC, Wong J. Somatostatin in the treatment of acute pancreatitis: a prospective randomised controlled trial. Gut. 1989;30(2):223–7.PubMedPubMedCentral Choi TK, Mok F, Zhan WH, Fan ST, Lai EC, Wong J. Somatostatin in the treatment of acute pancreatitis: a prospective randomised controlled trial. Gut. 1989;30(2):223–7.PubMedPubMedCentral
28.
go back to reference Uhl W, Buchler MW, Malfertheiner P, Beger HG, Adler G, Gaus W. A randomised, double blind, multicentre trial of octreotide in moderate to severe acute pancreatitis. Gut. 1999;45(1):97–104.PubMedPubMedCentral Uhl W, Buchler MW, Malfertheiner P, Beger HG, Adler G, Gaus W. A randomised, double blind, multicentre trial of octreotide in moderate to severe acute pancreatitis. Gut. 1999;45(1):97–104.PubMedPubMedCentral
29.
go back to reference D’Amico D, Favia G, Biasiato R, Casaccia M, Falcone F, Fersini M, et al. The use of somatostatin in acute pancreatitis—results of a multicenter trial. Hepatogastroenterology. 1990;37(1):92–8.PubMed D’Amico D, Favia G, Biasiato R, Casaccia M, Falcone F, Fersini M, et al. The use of somatostatin in acute pancreatitis—results of a multicenter trial. Hepatogastroenterology. 1990;37(1):92–8.PubMed
30.
go back to reference Luengo L, Vicente V, Gris F, Coronas JM, Escuder J, Ramon Gomez J, et al. Influence of somatostatin in the evolution of acute pancreatitis. A prospective randomized study. Int J Pancreatol. 1994;15(2):139–44.PubMed Luengo L, Vicente V, Gris F, Coronas JM, Escuder J, Ramon Gomez J, et al. Influence of somatostatin in the evolution of acute pancreatitis. A prospective randomized study. Int J Pancreatol. 1994;15(2):139–44.PubMed
31.
go back to reference Planas M, Perez A, Iglesia R, Porta I, Masclans JR, Bermejo B. Severe acute pancreatitis: treatment with somatostatin. Intensive Care Med. 1998;24(1):37–9.PubMed Planas M, Perez A, Iglesia R, Porta I, Masclans JR, Bermejo B. Severe acute pancreatitis: treatment with somatostatin. Intensive Care Med. 1998;24(1):37–9.PubMed
32.
go back to reference Binder M, Uhl W, Friess H, Malfertheiner P, Buchler MW. Octreotide in the treatment of acute pancreatitis: results of a unicenter prospective trial with three different octreotide dosages. Digestion. 1994;55 Suppl 1:20–3.PubMed Binder M, Uhl W, Friess H, Malfertheiner P, Buchler MW. Octreotide in the treatment of acute pancreatitis: results of a unicenter prospective trial with three different octreotide dosages. Digestion. 1994;55 Suppl 1:20–3.PubMed
33.
go back to reference McKay C, Baxter J, Imrie C. A randomized, controlled trial of octreotide in the management of patients with acute pancreatitis. Int J Pancreatol. 1997;21(1):13–9.PubMed McKay C, Baxter J, Imrie C. A randomized, controlled trial of octreotide in the management of patients with acute pancreatitis. Int J Pancreatol. 1997;21(1):13–9.PubMed
34.
go back to reference Xu W, Zhou YF, Xia SH: Octreotide for primary moderate to severe acute pancreatitis: a meta-analysis. Hepatogastroenterology (2013) 60(128). Xu W, Zhou YF, Xia SH: Octreotide for primary moderate to severe acute pancreatitis: a meta-analysis. Hepatogastroenterology (2013) 60(128).
35.
go back to reference Andriulli A, Leandro G, Clemente R, Festa V, Caruso N, Annese V, et al. Meta-analysis of somatostatin, octreotide and gabexate mesilate in the therapy of acute pancreatitis. Aliment Pharmacol Ther. 1998;12(3):237–45.PubMed Andriulli A, Leandro G, Clemente R, Festa V, Caruso N, Annese V, et al. Meta-analysis of somatostatin, octreotide and gabexate mesilate in the therapy of acute pancreatitis. Aliment Pharmacol Ther. 1998;12(3):237–45.PubMed
36.
go back to reference Wang R, Yang F, Wu H, Wang Y, Huang Z, Hu B, et al. High-dose versus low-dose octreotide in the treatment of acute pancreatitis: a randomized controlled trial. Peptides. 2013;40:57–64.PubMed Wang R, Yang F, Wu H, Wang Y, Huang Z, Hu B, et al. High-dose versus low-dose octreotide in the treatment of acute pancreatitis: a randomized controlled trial. Peptides. 2013;40:57–64.PubMed
37.
go back to reference Wang G, Wen J, Wilbur RR, Wen P, Zhou SF, Xiao X. The effect of somatostatin, ulinastatin and salvia miltiorrhiza on severe acute pancreatitis treatment. Am J Med Sci. 2013;346(5):371–6.PubMed Wang G, Wen J, Wilbur RR, Wen P, Zhou SF, Xiao X. The effect of somatostatin, ulinastatin and salvia miltiorrhiza on severe acute pancreatitis treatment. Am J Med Sci. 2013;346(5):371–6.PubMed
38.
go back to reference Yang F, Wu H, Li Y, Li Z, Wang C, Yang J, et al. Prevention of severe acute pancreatitis with octreotide in obese patients: a prospective multi-center randomized controlled trial. Pancreas. 2012;41(8):1206–12.PubMed Yang F, Wu H, Li Y, Li Z, Wang C, Yang J, et al. Prevention of severe acute pancreatitis with octreotide in obese patients: a prospective multi-center randomized controlled trial. Pancreas. 2012;41(8):1206–12.PubMed
39.
go back to reference Trapnell JE, Rigby CC, Talbot CH, Duncan EH. A controlled trial of Trasylol in the treatment of acute pancreatitis. Br J Surg. 1974;61(3):177–82.PubMed Trapnell JE, Rigby CC, Talbot CH, Duncan EH. A controlled trial of Trasylol in the treatment of acute pancreatitis. Br J Surg. 1974;61(3):177–82.PubMed
40.
go back to reference Berling R, Borgstrom A, Ohlsson K. Peritoneal lavage with aprotinin in patients with severe acute pancreatitis. Effects on plasma and peritoneal levels of trypsin and leukocyte proteases and their major inhibitors. Int J Pancreatol. 1998;24(1):9–17.PubMed Berling R, Borgstrom A, Ohlsson K. Peritoneal lavage with aprotinin in patients with severe acute pancreatitis. Effects on plasma and peritoneal levels of trypsin and leukocyte proteases and their major inhibitors. Int J Pancreatol. 1998;24(1):9–17.PubMed
41.
go back to reference Imrie CW, Benjamin IS, Ferguson JC, McKay AJ, Mackenzie I, O’Neill J, et al. A single-centre double-blind trial of Trasylol therapy in primary acute pancreatitis. Br J Surg. 1978;65(5):337–41.PubMed Imrie CW, Benjamin IS, Ferguson JC, McKay AJ, Mackenzie I, O’Neill J, et al. A single-centre double-blind trial of Trasylol therapy in primary acute pancreatitis. Br J Surg. 1978;65(5):337–41.PubMed
42.
go back to reference Morbidity of acute pancreatitis: the effect of aprotinin and glucagon. Gut (1980) 21(4):334–339. Morbidity of acute pancreatitis: the effect of aprotinin and glucagon. Gut (1980) 21(4):334–339.
43.
go back to reference Balldin G, Borgstrom A, Genell S, Ohlsson K. The effect of peritoneal lavage and aprotinin in the treatment of severe acute pancreatitis. Res Exp Med (Berl). 1983;183(3):203–13. Balldin G, Borgstrom A, Genell S, Ohlsson K. The effect of peritoneal lavage and aprotinin in the treatment of severe acute pancreatitis. Res Exp Med (Berl). 1983;183(3):203–13.
44.
go back to reference Berling R, Genell S, Ohlsson K. High-dose intraperitoneal aprotinin treatment of acute severe pancreatitis: a double-blind randomized multi-center trial. J Gastroenterol. 1994;29(4):479–85.PubMed Berling R, Genell S, Ohlsson K. High-dose intraperitoneal aprotinin treatment of acute severe pancreatitis: a double-blind randomized multi-center trial. J Gastroenterol. 1994;29(4):479–85.PubMed
45.
go back to reference Smith M, Kocher HM, Hunt BJ. Aprotinin in severe acute pancreatitis. Int J Clin Pract. 2010;64(1):84–92.PubMed Smith M, Kocher HM, Hunt BJ. Aprotinin in severe acute pancreatitis. Int J Clin Pract. 2010;64(1):84–92.PubMed
46.
go back to reference Wisner Jr JR, Renner IG, Grendell JH, Niederau C, Ferrell LD. Gabexate mesilate (FOY) protects against ceruletide-induced acute pancreatitis in the rat. Pancreas. 1987;2(2):181–6.PubMed Wisner Jr JR, Renner IG, Grendell JH, Niederau C, Ferrell LD. Gabexate mesilate (FOY) protects against ceruletide-induced acute pancreatitis in the rat. Pancreas. 1987;2(2):181–6.PubMed
47.
go back to reference Chen HM, Shyr MH, Chen MF. Gabexate mesilate improves pancreatic microcirculation and reduces lung edema in a rat model of acute pancreatitis. J Formos Med Assoc. 1997;96(9):704–9.PubMed Chen HM, Shyr MH, Chen MF. Gabexate mesilate improves pancreatic microcirculation and reduces lung edema in a rat model of acute pancreatitis. J Formos Med Assoc. 1997;96(9):704–9.PubMed
48.
go back to reference Freise J. Therapy of acute pancreatitis with a synthetic protease and phospholipase A2 inhibitor gabexate mesilate. Fortschr Med. 1983;101(31–32):1432–6.PubMed Freise J. Therapy of acute pancreatitis with a synthetic protease and phospholipase A2 inhibitor gabexate mesilate. Fortschr Med. 1983;101(31–32):1432–6.PubMed
49.
go back to reference Freise J, Melzer P, Schmidt FW, Horbach L. Gabexate mesilate in the treatment of acute pancreatitis. Results of a hannover multicenter double-blind study with 50 patients. Z Gastroenterol. 1986;24(4):200–11.PubMed Freise J, Melzer P, Schmidt FW, Horbach L. Gabexate mesilate in the treatment of acute pancreatitis. Results of a hannover multicenter double-blind study with 50 patients. Z Gastroenterol. 1986;24(4):200–11.PubMed
50.
go back to reference Chen HM, Chen JC, Hwang TL, Jan YY, Chen MF. Prospective and randomized study of gabexate mesilate for the treatment of severe acute pancreatitis with organ dysfunction. Hepatogastroenterology. 2000;47(34):1147–50.PubMed Chen HM, Chen JC, Hwang TL, Jan YY, Chen MF. Prospective and randomized study of gabexate mesilate for the treatment of severe acute pancreatitis with organ dysfunction. Hepatogastroenterology. 2000;47(34):1147–50.PubMed
51.•
go back to reference Seta T, Noguchi Y, Shikata S, Nakayama T. Treatment of acute pancreatitis with protease inhibitors administered through intravenous infusion: an updated systematic review and meta-analysis. BMC Gastroenterol. 2014;14:102. Most up-to-date meta-analysis with articles of randomized controlled trials published from January1965 to March 2013 on the effectiveness of protease inhibitors for acute pancreatitis. confirmed that there is no solid evidence that supports the intravenous use of protease inhibitors to prevent death due to acute pancreatitis.PubMedPubMedCentral Seta T, Noguchi Y, Shikata S, Nakayama T. Treatment of acute pancreatitis with protease inhibitors administered through intravenous infusion: an updated systematic review and meta-analysis. BMC Gastroenterol. 2014;14:102. Most up-to-date meta-analysis with articles of randomized controlled trials published from January1965 to March 2013 on the effectiveness of protease inhibitors for acute pancreatitis. confirmed that there is no solid evidence that supports the intravenous use of protease inhibitors to prevent death due to acute pancreatitis.PubMedPubMedCentral
52.
go back to reference Buchler M, Malfertheiner P, Uhl W, Scholmerich J, Stockmann F, Adler G, et al. Gabexate mesilate in human acute pancreatitis. German pancreatitis study group. Gastroenterology. 1993;104(4):1165–70.PubMed Buchler M, Malfertheiner P, Uhl W, Scholmerich J, Stockmann F, Adler G, et al. Gabexate mesilate in human acute pancreatitis. German pancreatitis study group. Gastroenterology. 1993;104(4):1165–70.PubMed
53.
go back to reference Harada H, Miyake H, Ochi K, Tanaka J, Kimura I. Clinical trial with a protease inhibitor gabexate mesilate in acute pancreatitis. Int J Pancreatol. 1991;9:75–9.PubMed Harada H, Miyake H, Ochi K, Tanaka J, Kimura I. Clinical trial with a protease inhibitor gabexate mesilate in acute pancreatitis. Int J Pancreatol. 1991;9:75–9.PubMed
54.
go back to reference Tympner F, Rosch W. Effect of secretin and gabexate-mesilate (synthetic protease inhibitor) on serum amylase level after ERCP. Z Gastroenterol. 1982;20(11):688–93.PubMed Tympner F, Rosch W. Effect of secretin and gabexate-mesilate (synthetic protease inhibitor) on serum amylase level after ERCP. Z Gastroenterol. 1982;20(11):688–93.PubMed
55.
go back to reference Valderrama R, Perez-Mateo M, Navarro S, Vazquez N, Sanjose L, Adrian MJ, et al. Multicenter double-blind trial of gabexate mesylate (FOY) in unselected patients with acute pancreatitis. Digestion. 1992;51(2):65–70.PubMed Valderrama R, Perez-Mateo M, Navarro S, Vazquez N, Sanjose L, Adrian MJ, et al. Multicenter double-blind trial of gabexate mesylate (FOY) in unselected patients with acute pancreatitis. Digestion. 1992;51(2):65–70.PubMed
56.
go back to reference Yang CY, Chang-Chien CS, Liaw YF. Controlled trial of protease inhibitor gabexelate mesilate (FOY) in the treatment of acute pancreatitis. Pancreas. 1987;2(6):698–700.PubMed Yang CY, Chang-Chien CS, Liaw YF. Controlled trial of protease inhibitor gabexelate mesilate (FOY) in the treatment of acute pancreatitis. Pancreas. 1987;2(6):698–700.PubMed
57.
go back to reference Pezzilli RBB, Morselli-Labate AM. Evaluation of the immunomodulatory effect of gabexate mesilate in patients with severe acute pancreatitis. Curr Ther Res. 1998;59:710–6. Pezzilli RBB, Morselli-Labate AM. Evaluation of the immunomodulatory effect of gabexate mesilate in patients with severe acute pancreatitis. Curr Ther Res. 1998;59:710–6.
58.
go back to reference Heinrich S, Schafer M, Rousson V, Clavien PA. Evidence-based treatment of acute pancreatitis: a look at established paradigms. Ann Surg. 2006;243(2):154–68.PubMedPubMedCentral Heinrich S, Schafer M, Rousson V, Clavien PA. Evidence-based treatment of acute pancreatitis: a look at established paradigms. Ann Surg. 2006;243(2):154–68.PubMedPubMedCentral
59.
go back to reference Wang X, Zhuang X, Wei R, Wang C, Xue X, Mao L. Protective effects of Acanthopanax vs. Ulinastatin against severe acute pancreatitis-induced brain injury in rats. Int Immunopharmacol. 2014;24(2):285–98.PubMed Wang X, Zhuang X, Wei R, Wang C, Xue X, Mao L. Protective effects of Acanthopanax vs. Ulinastatin against severe acute pancreatitis-induced brain injury in rats. Int Immunopharmacol. 2014;24(2):285–98.PubMed
60.
go back to reference Tsujino T, Komatsu Y, Isayama H, Hirano K, Sasahira N, Yamamoto N, et al. Ulinastatin for pancreatitis after endoscopic retrograde cholangiopancreatography: a randomized, controlled trial. Clin Gastroenterol Hepatol. 2005;3(4):376–83.PubMed Tsujino T, Komatsu Y, Isayama H, Hirano K, Sasahira N, Yamamoto N, et al. Ulinastatin for pancreatitis after endoscopic retrograde cholangiopancreatography: a randomized, controlled trial. Clin Gastroenterol Hepatol. 2005;3(4):376–83.PubMed
61.
go back to reference Abraham P, Rodriques J, Moulick N, Dharap S, Chafekar N, Verma PK, et al. Efficacy and safety of intravenous ulinastatin versus placebo along with standard supportive care in subjects with mild or severe acute pancreatitis. J Assoc Physicians India. 2013;61(8):535–8.PubMed Abraham P, Rodriques J, Moulick N, Dharap S, Chafekar N, Verma PK, et al. Efficacy and safety of intravenous ulinastatin versus placebo along with standard supportive care in subjects with mild or severe acute pancreatitis. J Assoc Physicians India. 2013;61(8):535–8.PubMed
62.
go back to reference Yamauchi J, Takeda K, Shibuya K, Sunamura M, Matsuno S. Continuous regional application of protease inhibitor in the treatment of acute pancreatitis. An experimental study using closed duodenal obstruction model in dogs. Pancreatology. 2001;1(6):662–7.PubMed Yamauchi J, Takeda K, Shibuya K, Sunamura M, Matsuno S. Continuous regional application of protease inhibitor in the treatment of acute pancreatitis. An experimental study using closed duodenal obstruction model in dogs. Pancreatology. 2001;1(6):662–7.PubMed
63.
go back to reference Imaizumi H, Kida M, Nishimaki H, Okuno J, Kataoka Y, Kida Y, et al. Efficacy of continuous regional arterial infusion of a protease inhibitor and antibiotic for severe acute pancreatitis in patients admitted to an intensive care unit. Pancreas. 2004;28(4):369–73.PubMed Imaizumi H, Kida M, Nishimaki H, Okuno J, Kataoka Y, Kida Y, et al. Efficacy of continuous regional arterial infusion of a protease inhibitor and antibiotic for severe acute pancreatitis in patients admitted to an intensive care unit. Pancreas. 2004;28(4):369–73.PubMed
64.
go back to reference Piascik M, Rydzewska G, Milewski J, Olszewski S, Furmanek M, Walecki J, et al. The results of severe acute pancreatitis treatment with continuous regional arterial infusion of protease inhibitor and antibiotic: a randomized controlled study. Pancreas. 2010;39(6):863–7.PubMed Piascik M, Rydzewska G, Milewski J, Olszewski S, Furmanek M, Walecki J, et al. The results of severe acute pancreatitis treatment with continuous regional arterial infusion of protease inhibitor and antibiotic: a randomized controlled study. Pancreas. 2010;39(6):863–7.PubMed
65.
go back to reference Takeda K, Matsuno S, Ogawa M, Watanabe S, Atomi Y. Continuous regional arterial infusion (CRAI) therapy reduces the mortality rate of acute necrotizing pancreatitis: results of a cooperative survey in Japan. J Hepatobiliary Pancreat Surg. 2001;8(3):216–20.PubMed Takeda K, Matsuno S, Ogawa M, Watanabe S, Atomi Y. Continuous regional arterial infusion (CRAI) therapy reduces the mortality rate of acute necrotizing pancreatitis: results of a cooperative survey in Japan. J Hepatobiliary Pancreat Surg. 2001;8(3):216–20.PubMed
66.
go back to reference Takeda K, Matsuno S, Sunamura M, Kakugawa Y. Continuous regional arterial infusion of protease inhibitor and antibiotics in acute necrotizing pancreatitis. Am J Surg. 1996;171(4):394–8.PubMed Takeda K, Matsuno S, Sunamura M, Kakugawa Y. Continuous regional arterial infusion of protease inhibitor and antibiotics in acute necrotizing pancreatitis. Am J Surg. 1996;171(4):394–8.PubMed
67.
go back to reference Takeda K, Yamauchi J, Shibuya K, Sunamura M, Mikami Y, Matsuno S. Benefit of continuous regional arterial infusion of protease inhibitor and antibiotic in the management of acute necrotizing pancreatitis. Pancreatology. 2001;1(6):668–73.PubMed Takeda K, Yamauchi J, Shibuya K, Sunamura M, Mikami Y, Matsuno S. Benefit of continuous regional arterial infusion of protease inhibitor and antibiotic in the management of acute necrotizing pancreatitis. Pancreatology. 2001;1(6):668–73.PubMed
68.
go back to reference Ishikawa T, Imai M, Kamimura H, Ushiki T, Tsuchiya A, Togashi T, et al. Therapeutic efficacy of continuous arterial infusion of the protease inhibitor and the antibiotics and via celiac and superior mesenteric artery for severe acute pancreatitis—pilot study. Hepatogastroenterology. 2009;56(90):524–8.PubMed Ishikawa T, Imai M, Kamimura H, Ushiki T, Tsuchiya A, Togashi T, et al. Therapeutic efficacy of continuous arterial infusion of the protease inhibitor and the antibiotics and via celiac and superior mesenteric artery for severe acute pancreatitis—pilot study. Hepatogastroenterology. 2009;56(90):524–8.PubMed
69.
go back to reference Ino Y, Arita Y, Akashi T, Kimura T, Igarashi H, Oono T, et al. Continuous regional arterial infusion therapy with gabexate mesilate for severe acute pancreatitis. World J Gastroenterol. 2008;14(41):6382–7.PubMedPubMedCentral Ino Y, Arita Y, Akashi T, Kimura T, Igarashi H, Oono T, et al. Continuous regional arterial infusion therapy with gabexate mesilate for severe acute pancreatitis. World J Gastroenterol. 2008;14(41):6382–7.PubMedPubMedCentral
70.
go back to reference Anai H, Sakaguchi H, Uchida H, Matsuo N, Tanaka T, Yoshioka T, et al. Continuous arterial infusion therapy for severe acute pancreatitis: correlation between ct arteriography and therapeutic effect. J Vasc Interv Radiol. 1999;10(10):1335–42.PubMed Anai H, Sakaguchi H, Uchida H, Matsuo N, Tanaka T, Yoshioka T, et al. Continuous arterial infusion therapy for severe acute pancreatitis: correlation between ct arteriography and therapeutic effect. J Vasc Interv Radiol. 1999;10(10):1335–42.PubMed
71.
go back to reference Shanbhag ST, Petrov MS, Windsor JA. Is continuous regional arterial infusion of antiproteases now a standard of care in the treatment of acute pancreatitis? Pancreas. 2011;40(7):1141.PubMed Shanbhag ST, Petrov MS, Windsor JA. Is continuous regional arterial infusion of antiproteases now a standard of care in the treatment of acute pancreatitis? Pancreas. 2011;40(7):1141.PubMed
72.
go back to reference Braganza JM, Scott P, Bilton D, Schofield D, Chaloner C, Shiel N, et al. Evidence for early oxidative stress in acute pancreatitis. Clues for correction. Int J Pancreatol. 1995;17(1):69–81.PubMed Braganza JM, Scott P, Bilton D, Schofield D, Chaloner C, Shiel N, et al. Evidence for early oxidative stress in acute pancreatitis. Clues for correction. Int J Pancreatol. 1995;17(1):69–81.PubMed
73.
go back to reference Dabrowski A, Konturek SJ, Konturek JW, Gabryelewicz A. Role of oxidative stress in the pathogenesis of caerulein-induced acute pancreatitis. Eur J Pharmacol. 1999;377(1):1–11.PubMed Dabrowski A, Konturek SJ, Konturek JW, Gabryelewicz A. Role of oxidative stress in the pathogenesis of caerulein-induced acute pancreatitis. Eur J Pharmacol. 1999;377(1):1–11.PubMed
74.
go back to reference Demols A, Van Laethem JL, Quertinmont E, Legros F, Louis H, Le Moine O, et al. N-acetylcysteine decreases severity of acute pancreatitis in mice. Pancreas. 2000;20(2):161–9.PubMed Demols A, Van Laethem JL, Quertinmont E, Legros F, Louis H, Le Moine O, et al. N-acetylcysteine decreases severity of acute pancreatitis in mice. Pancreas. 2000;20(2):161–9.PubMed
75.
go back to reference Esrefoglu M, Gul M, Ates B, Yilmaz I. Ultrastructural clues for the protective effect of ascorbic acid and n-acetylcysteine against oxidative damage on caerulein-induced pancreatitis. Pancreatology. 2006;6(5):477–85.PubMed Esrefoglu M, Gul M, Ates B, Yilmaz I. Ultrastructural clues for the protective effect of ascorbic acid and n-acetylcysteine against oxidative damage on caerulein-induced pancreatitis. Pancreatology. 2006;6(5):477–85.PubMed
76.
go back to reference Fu K, Sarras Jr MP, De Lisle RC, Andrews GK. Expression of oxidative stress-responsive genes and cytokine genes during caerulein-induced acute pancreatitis. Am J Physiol. 1997;273(3 Pt 1):G696–705.PubMed Fu K, Sarras Jr MP, De Lisle RC, Andrews GK. Expression of oxidative stress-responsive genes and cytokine genes during caerulein-induced acute pancreatitis. Am J Physiol. 1997;273(3 Pt 1):G696–705.PubMed
77.
go back to reference Manso MA, Ramudo L, De Dios I. Extrapancreatic organ impairment during acute pancreatitis induced by bile-pancreatic duct obstruction. Effect of n-acetylcysteine. Int J Exp Pathol. 2007;88(5):343–9.PubMedPubMedCentral Manso MA, Ramudo L, De Dios I. Extrapancreatic organ impairment during acute pancreatitis induced by bile-pancreatic duct obstruction. Effect of n-acetylcysteine. Int J Exp Pathol. 2007;88(5):343–9.PubMedPubMedCentral
78.
go back to reference Mumcu S, Alhan E, Turkyilmaz S, Kural BV, Ercin C, Kalyoncu NI. Effects of n-acetylcysteine on acute necrotizing pancreatitis in rats. Eur Surg Res. 2005;37(3):173–8.PubMed Mumcu S, Alhan E, Turkyilmaz S, Kural BV, Ercin C, Kalyoncu NI. Effects of n-acetylcysteine on acute necrotizing pancreatitis in rats. Eur Surg Res. 2005;37(3):173–8.PubMed
79.
go back to reference Neuschwander-Tetri BA, Ferrell LD, Sukhabote RJ, Grendell JH. Glutathione monoethyl ester ameliorates caerulein-induced pancreatitis in the mouse. J Clin Invest. 1992;89(1):109–16.PubMedPubMedCentral Neuschwander-Tetri BA, Ferrell LD, Sukhabote RJ, Grendell JH. Glutathione monoethyl ester ameliorates caerulein-induced pancreatitis in the mouse. J Clin Invest. 1992;89(1):109–16.PubMedPubMedCentral
80.
go back to reference Ramudo L, Manso MA, Vicente S, De Dios I. Pro- and anti-inflammatory response of acinar cells during acute pancreatitis. Effect of n-acetyl cysteine. Cytokine. 2005;32(3–4):125–31.PubMed Ramudo L, Manso MA, Vicente S, De Dios I. Pro- and anti-inflammatory response of acinar cells during acute pancreatitis. Effect of n-acetyl cysteine. Cytokine. 2005;32(3–4):125–31.PubMed
81.
go back to reference Rau B, Poch B, Gansauge F, Bauer A, Nussler AK, Nevalainen T, et al. Pathophysiologic role of oxygen free radicals in acute pancreatitis: initiating event or mediator of tissue damage? Ann Surg. 2000;231(3):352–60.PubMedPubMedCentral Rau B, Poch B, Gansauge F, Bauer A, Nussler AK, Nevalainen T, et al. Pathophysiologic role of oxygen free radicals in acute pancreatitis: initiating event or mediator of tissue damage? Ann Surg. 2000;231(3):352–60.PubMedPubMedCentral
82.
go back to reference Sevillano S, De la Mano AM, De Dios I, Ramudo L, Manso MA. Major pathological mechanisms of acute pancreatitis are prevented by n-acetylcysteine. Digestion. 2003;68(1):34–40.PubMed Sevillano S, De la Mano AM, De Dios I, Ramudo L, Manso MA. Major pathological mechanisms of acute pancreatitis are prevented by n-acetylcysteine. Digestion. 2003;68(1):34–40.PubMed
83.
go back to reference Sweiry JH, Mann GE. Role of oxidative stress in the pathogenesis of acute pancreatitis. Scand J Gastroenterol Suppl. 1996;219:10–5.PubMed Sweiry JH, Mann GE. Role of oxidative stress in the pathogenesis of acute pancreatitis. Scand J Gastroenterol Suppl. 1996;219:10–5.PubMed
84.
go back to reference Hackert T, Werner J. Antioxidant therapy in acute pancreatitis: experimental and clinical evidence. Antioxid Redox Signal. 2011;15(10):2767–77.PubMed Hackert T, Werner J. Antioxidant therapy in acute pancreatitis: experimental and clinical evidence. Antioxid Redox Signal. 2011;15(10):2767–77.PubMed
85.
go back to reference Du WD, Yuan ZR, Sun J, Tang JX, Cheng AQ, Shen DM, et al. Therapeutic efficacy of high-dose vitamin c on acute pancreatitis and its potential mechanisms. World J Gastroenterol. 2003;9(11):2565–9.PubMedPubMedCentral Du WD, Yuan ZR, Sun J, Tang JX, Cheng AQ, Shen DM, et al. Therapeutic efficacy of high-dose vitamin c on acute pancreatitis and its potential mechanisms. World J Gastroenterol. 2003;9(11):2565–9.PubMedPubMedCentral
86.
go back to reference Kuklinski B, Zimmermann T, Schweder R. Decreasing mortality in acute pancreatitis with sodium selenite. Clinical results of 4 years antioxidant therapy. Med Klin (Munich). 1995;90 Suppl 1:36–41. Kuklinski B, Zimmermann T, Schweder R. Decreasing mortality in acute pancreatitis with sodium selenite. Clinical results of 4 years antioxidant therapy. Med Klin (Munich). 1995;90 Suppl 1:36–41.
87.
go back to reference Lindner D, Lindner J, Baumann G, Dawczynski H, Bauch K. Investigation of antioxidant therapy with sodium selenite in acute pancreatitis. A prospective randomized blind trial. Med Klin (Munich). 2004;99(12):708–12. Lindner D, Lindner J, Baumann G, Dawczynski H, Bauch K. Investigation of antioxidant therapy with sodium selenite in acute pancreatitis. A prospective randomized blind trial. Med Klin (Munich). 2004;99(12):708–12.
88.
go back to reference Siriwardena AK, Mason JM, Balachandra S, Bagul A, Galloway S, Formela L, et al. Randomised, double blind, placebo controlled trial of intravenous antioxidant (n-acetylcysteine, selenium, vitamin c) therapy in severe acute pancreatitis. Gut. 2007;56(10):1439–44.PubMedPubMedCentral Siriwardena AK, Mason JM, Balachandra S, Bagul A, Galloway S, Formela L, et al. Randomised, double blind, placebo controlled trial of intravenous antioxidant (n-acetylcysteine, selenium, vitamin c) therapy in severe acute pancreatitis. Gut. 2007;56(10):1439–44.PubMedPubMedCentral
89.
go back to reference Bansal D, Bhalla A, Bhasin DK, Pandhi P, Sharma N, Rana S, et al. Safety and efficacy of vitamin-based antioxidant therapy in patients with severe acute pancreatitis: a randomized controlled trial. Saudi J Gastroenterol. 2011;17(3):174–9.PubMedPubMedCentral Bansal D, Bhalla A, Bhasin DK, Pandhi P, Sharma N, Rana S, et al. Safety and efficacy of vitamin-based antioxidant therapy in patients with severe acute pancreatitis: a randomized controlled trial. Saudi J Gastroenterol. 2011;17(3):174–9.PubMedPubMedCentral
90.
go back to reference Sateesh J, Bhardwaj P, Singh N, Saraya A. Effect of antioxidant therapy on hospital stay and complications in patients with early acute pancreatitis: a randomised controlled trial. Trop Gastroenterol. 2009;30(4):201–6.PubMed Sateesh J, Bhardwaj P, Singh N, Saraya A. Effect of antioxidant therapy on hospital stay and complications in patients with early acute pancreatitis: a randomised controlled trial. Trop Gastroenterol. 2009;30(4):201–6.PubMed
91.
go back to reference Xue P, Deng LH, Xia Q, Zhang ZD, Hu WM, Yang XN, et al. Impact of alanyl-glutamine dipeptide on severe acute pancreatitis in early stage. World J Gastroenterol. 2008;14(3):474–8.PubMedPubMedCentral Xue P, Deng LH, Xia Q, Zhang ZD, Hu WM, Yang XN, et al. Impact of alanyl-glutamine dipeptide on severe acute pancreatitis in early stage. World J Gastroenterol. 2008;14(3):474–8.PubMedPubMedCentral
92.
go back to reference Asrani V, Chang WK, Dong Z, Hardy G, Windsor JA, Petrov MS. Glutamine supplementation in acute pancreatitis: a meta-analysis of randomized controlled trials. Pancreatology. 2013;13(5):468–74.PubMed Asrani V, Chang WK, Dong Z, Hardy G, Windsor JA, Petrov MS. Glutamine supplementation in acute pancreatitis: a meta-analysis of randomized controlled trials. Pancreatology. 2013;13(5):468–74.PubMed
93.
go back to reference Coelle EF, Adham N, Elashoff J, Lewin K, Taylor IL. Effects of prostaglandin and indomethacin on diet-induced acute pancreatitis in mice. Gastroenterology. 1983;85(6):1307–12.PubMed Coelle EF, Adham N, Elashoff J, Lewin K, Taylor IL. Effects of prostaglandin and indomethacin on diet-induced acute pancreatitis in mice. Gastroenterology. 1983;85(6):1307–12.PubMed
94.
go back to reference Foitzik T, Hotz HG, Hotz B, Wittig F, Buhr HJ. Selective inhibition of cyclooxygenase-2 (COX-2) reduces prostaglandin E2 production and attenuates systemic disease sequelae in experimental pancreatitis. Hepatogastroenterology. 2003;50(52):1159–62.PubMed Foitzik T, Hotz HG, Hotz B, Wittig F, Buhr HJ. Selective inhibition of cyclooxygenase-2 (COX-2) reduces prostaglandin E2 production and attenuates systemic disease sequelae in experimental pancreatitis. Hepatogastroenterology. 2003;50(52):1159–62.PubMed
95.
go back to reference Ebbehoj N, Friis J, Svendsen LB, Bulow S, Madsen P. Indomethacin treatment of acute pancreatitis. A controlled double-blind trial. Scand J Gastroenterol. 1985;20(7):798–800.PubMed Ebbehoj N, Friis J, Svendsen LB, Bulow S, Madsen P. Indomethacin treatment of acute pancreatitis. A controlled double-blind trial. Scand J Gastroenterol. 1985;20(7):798–800.PubMed
96.
go back to reference Emanuelli G, Montrucchio G, Gaia E, Dughera L, Corvetti G, Gubetta L. Experimental acute pancreatitis induced by platelet activating factor in rabbits. Am J Pathol. 1989;134(2):315–26.PubMedPubMedCentral Emanuelli G, Montrucchio G, Gaia E, Dughera L, Corvetti G, Gubetta L. Experimental acute pancreatitis induced by platelet activating factor in rabbits. Am J Pathol. 1989;134(2):315–26.PubMedPubMedCentral
97.
go back to reference Kald B, Kald A, Ihse I, Tagesson C. Release of platelet-activating factor in acute experimental pancreatitis. Pancreas. 1993;8(4):440–2.PubMed Kald B, Kald A, Ihse I, Tagesson C. Release of platelet-activating factor in acute experimental pancreatitis. Pancreas. 1993;8(4):440–2.PubMed
98.
go back to reference Dabrowski A, Gabryelewicz A, Chyczewski L. The effect of platelet activating factor antagonist (bn 52021) on cerulein-induced acute pancreatitis with reference to oxygen radicals. Int J Pancreatol. 1991;8(1):1–11.PubMed Dabrowski A, Gabryelewicz A, Chyczewski L. The effect of platelet activating factor antagonist (bn 52021) on cerulein-induced acute pancreatitis with reference to oxygen radicals. Int J Pancreatol. 1991;8(1):1–11.PubMed
99.
go back to reference Jancar S, De Giaccobi G, Mariano M, Mencia-Huerta JM, Sirois P, Braquet P. Immune complex induced pancreatitis: effect of BN 52021, a selective antagonist of platelet-activating factor. Prostaglandins. 1988;35(5):757–70.PubMed Jancar S, De Giaccobi G, Mariano M, Mencia-Huerta JM, Sirois P, Braquet P. Immune complex induced pancreatitis: effect of BN 52021, a selective antagonist of platelet-activating factor. Prostaglandins. 1988;35(5):757–70.PubMed
100.
go back to reference Lane JS, Todd KE, Gloor B, Chandler CF, Kau AW, Ashley SW, et al. Platelet activating factor antagonism reduces the systemic inflammatory response in a murine model of acute pancreatitis. J Surg Res. 2001;99(2):365–70.PubMed Lane JS, Todd KE, Gloor B, Chandler CF, Kau AW, Ashley SW, et al. Platelet activating factor antagonism reduces the systemic inflammatory response in a murine model of acute pancreatitis. J Surg Res. 2001;99(2):365–70.PubMed
101.
go back to reference Leveau P, Wang X, Sun Z, Borjesson A, Andersson E, Andersson R. Severity of pancreatitis-associated gut barrier dysfunction is reduced following treatment with the PAF inhibitor lexipafant. Biochem Pharmacol. 2005;69(9):1325–31.PubMed Leveau P, Wang X, Sun Z, Borjesson A, Andersson E, Andersson R. Severity of pancreatitis-associated gut barrier dysfunction is reduced following treatment with the PAF inhibitor lexipafant. Biochem Pharmacol. 2005;69(9):1325–31.PubMed
102.
go back to reference Kingsnorth AN, Galloway SW, Formela LJ. Randomized, double-blind phase ii trial of lexipafant, a platelet-activating factor antagonist, in human acute pancreatitis. Br J Surg. 1995;82(10):1414–20.PubMed Kingsnorth AN, Galloway SW, Formela LJ. Randomized, double-blind phase ii trial of lexipafant, a platelet-activating factor antagonist, in human acute pancreatitis. Br J Surg. 1995;82(10):1414–20.PubMed
103.
go back to reference McKay CJ, Curran F, Sharples C, Baxter JN, Imrie CW. Prospective placebo-controlled randomized trial of lexipafant in predicted severe acute pancreatitis. Br J Surg. 1997;84(9):1239–43.PubMed McKay CJ, Curran F, Sharples C, Baxter JN, Imrie CW. Prospective placebo-controlled randomized trial of lexipafant in predicted severe acute pancreatitis. Br J Surg. 1997;84(9):1239–43.PubMed
104.
go back to reference Johnson CD, Kingsnorth AN, Imrie CW, McMahon MJ, Neoptolemos JP, McKay C, et al. Double blind, randomised, placebo controlled study of a platelet activating factor antagonist, lexipafant, in the treatment and prevention of organ failure in predicted severe acute pancreatitis. Gut. 2001;48(1):62–9.PubMedPubMedCentral Johnson CD, Kingsnorth AN, Imrie CW, McMahon MJ, Neoptolemos JP, McKay C, et al. Double blind, randomised, placebo controlled study of a platelet activating factor antagonist, lexipafant, in the treatment and prevention of organ failure in predicted severe acute pancreatitis. Gut. 2001;48(1):62–9.PubMedPubMedCentral
105.
go back to reference Petrov MS, Pylypchuk RD. Prophylactic antibiotic treatment in acute necrotizing pancreatitis: East wind blows no good. Scand J Gastroenterol. 2009;44(5):637–8. author reply 639–640.PubMed Petrov MS, Pylypchuk RD. Prophylactic antibiotic treatment in acute necrotizing pancreatitis: East wind blows no good. Scand J Gastroenterol. 2009;44(5):637–8. author reply 639–640.PubMed
106.
go back to reference van Minnen LP, Timmerman HM, Lutgendorff F, Verheem A, Harmsen W, Konstantinov SR, et al. Modification of intestinal flora with multispecies probiotics reduces bacterial translocation and improves clinical course in a rat model of acute pancreatitis. Surgery. 2007;141(4):470–80.PubMed van Minnen LP, Timmerman HM, Lutgendorff F, Verheem A, Harmsen W, Konstantinov SR, et al. Modification of intestinal flora with multispecies probiotics reduces bacterial translocation and improves clinical course in a rat model of acute pancreatitis. Surgery. 2007;141(4):470–80.PubMed
107.
go back to reference Akyol S, Mas MR, Comert B, Ateskan U, Yasar M, Aydogan H, et al. The effect of antibiotic and probiotic combination therapy on secondary pancreatic infections and oxidative stress parameters in experimental acute necrotizing pancreatitis. Pancreas. 2003;26(4):363–7.PubMed Akyol S, Mas MR, Comert B, Ateskan U, Yasar M, Aydogan H, et al. The effect of antibiotic and probiotic combination therapy on secondary pancreatic infections and oxidative stress parameters in experimental acute necrotizing pancreatitis. Pancreas. 2003;26(4):363–7.PubMed
108.
go back to reference Muftuoglu MA, Isikgor S, Tosun S, Saglam A. Effects of probiotics on the severity of experimental acute pancreatitis. Eur J Clin Nutr. 2006;60(4):464–8.PubMed Muftuoglu MA, Isikgor S, Tosun S, Saglam A. Effects of probiotics on the severity of experimental acute pancreatitis. Eur J Clin Nutr. 2006;60(4):464–8.PubMed
109.
go back to reference Karen M, Yuksel O, Akyurek N, Ofluoglu E, Caglar K, Sahin TT, et al. Probiotic agent saccharomyces boulardii reduces the incidence of lung injury in acute necrotizing pancreatitis induced rats. J Surg Res. 2010;160(1):139–44.PubMed Karen M, Yuksel O, Akyurek N, Ofluoglu E, Caglar K, Sahin TT, et al. Probiotic agent saccharomyces boulardii reduces the incidence of lung injury in acute necrotizing pancreatitis induced rats. J Surg Res. 2010;160(1):139–44.PubMed
110.
go back to reference Olah A, Belagyi T, Issekutz A, Gamal ME, Bengmark S. Randomized clinical trial of specific lactobacillus and fibre supplement to early enteral nutrition in patients with acute pancreatitis. Br J Surg. 2002;89(9):1103–7.PubMed Olah A, Belagyi T, Issekutz A, Gamal ME, Bengmark S. Randomized clinical trial of specific lactobacillus and fibre supplement to early enteral nutrition in patients with acute pancreatitis. Br J Surg. 2002;89(9):1103–7.PubMed
111.
go back to reference Olah A, Belagyi T, Poto L, Romics Jr L, Bengmark S. Synbiotic control of inflammation and infection in severe acute pancreatitis: a prospective, randomized, double blind study. Hepatogastroenterology. 2007;54(74):590–4.PubMed Olah A, Belagyi T, Poto L, Romics Jr L, Bengmark S. Synbiotic control of inflammation and infection in severe acute pancreatitis: a prospective, randomized, double blind study. Hepatogastroenterology. 2007;54(74):590–4.PubMed
112.
go back to reference Besselink MG, van Santvoort HC, Buskens E, Boermeester MA, van Goor H, Timmerman HM, et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;371(9613):651–9.PubMed Besselink MG, van Santvoort HC, Buskens E, Boermeester MA, van Goor H, Timmerman HM, et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;371(9613):651–9.PubMed
113.•
go back to reference Plaudis H, Pupelis G, Zeiza K, Boka V. Early low volume oral synbiotic/prebiotic supplemented enteral stimulation of the gut in patients with severe acute pancreatitis: a prospective feasibility study. Acta Chir Belg. 2012;112(2):131–8. A systematic review of all randomized controlled trials shows probiotics neither beneficial nor adverse effects on the clinical outcomes of patients with predicted SAP.PubMed Plaudis H, Pupelis G, Zeiza K, Boka V. Early low volume oral synbiotic/prebiotic supplemented enteral stimulation of the gut in patients with severe acute pancreatitis: a prospective feasibility study. Acta Chir Belg. 2012;112(2):131–8. A systematic review of all randomized controlled trials shows probiotics neither beneficial nor adverse effects on the clinical outcomes of patients with predicted SAP.PubMed
114.
go back to reference Gou S, Yang Z, Liu T, Wu H, Wang C. Use of probiotics in the treatment of severe acute pancreatitis: a systematic review and meta-analysis of randomized controlled trials. Crit Care. 2014;18(2):R57.PubMedPubMedCentral Gou S, Yang Z, Liu T, Wu H, Wang C. Use of probiotics in the treatment of severe acute pancreatitis: a systematic review and meta-analysis of randomized controlled trials. Crit Care. 2014;18(2):R57.PubMedPubMedCentral
115.
go back to reference Toltl LJ, Austin RC, Liaw PC. Activated protein c modulates inflammation, apoptosis and tissue factor procoagulant activity by regulating endoplasmic reticulum calcium depletion in blood monocytes. J Thromb Haemost. 2011;9(3):582–92.PubMed Toltl LJ, Austin RC, Liaw PC. Activated protein c modulates inflammation, apoptosis and tissue factor procoagulant activity by regulating endoplasmic reticulum calcium depletion in blood monocytes. J Thromb Haemost. 2011;9(3):582–92.PubMed
116.
go back to reference Alsfasser G, Warshaw AL, Thayer SP, Antoniu B, Laposata M, Lewandrowski KB, et al. Decreased inflammation and improved survival with recombinant human activated protein C treatment in experimental acute pancreatitis. Arch Surg. 2006;141(7):670–6. discussion 676–677.PubMedPubMedCentral Alsfasser G, Warshaw AL, Thayer SP, Antoniu B, Laposata M, Lewandrowski KB, et al. Decreased inflammation and improved survival with recombinant human activated protein C treatment in experimental acute pancreatitis. Arch Surg. 2006;141(7):670–6. discussion 676–677.PubMedPubMedCentral
117.
go back to reference Chen P, Zhang Y, Qiao M, Yuan Y. Activated protein c, an anticoagulant polypeptide, ameliorates severe acute pancreatitis via regulation of mitogen-activated protein kinases. J Gastroenterol. 2007;42(11):887–96.PubMed Chen P, Zhang Y, Qiao M, Yuan Y. Activated protein c, an anticoagulant polypeptide, ameliorates severe acute pancreatitis via regulation of mitogen-activated protein kinases. J Gastroenterol. 2007;42(11):887–96.PubMed
118.
go back to reference Yamanel L, Mas MR, Comert B, Isik AT, Aydin S, Mas N, et al. The effect of activated protein C on experimental acute necrotizing pancreatitis. Crit Care. 2005;9(3):R184–90.PubMed Yamanel L, Mas MR, Comert B, Isik AT, Aydin S, Mas N, et al. The effect of activated protein C on experimental acute necrotizing pancreatitis. Crit Care. 2005;9(3):R184–90.PubMed
119.
go back to reference Pettila V, Kyhala L, Kylanpaa ML, Leppaniemi A, Tallgren M, Markkola A, et al. APCAP—activated protein c in acute pancreatitis: a double-blind randomized human pilot trial. Crit Care. 2010;14(4):R139.PubMedPubMedCentral Pettila V, Kyhala L, Kylanpaa ML, Leppaniemi A, Tallgren M, Markkola A, et al. APCAP—activated protein c in acute pancreatitis: a double-blind randomized human pilot trial. Crit Care. 2010;14(4):R139.PubMedPubMedCentral
120.
go back to reference Kyhala L, Mentula P, Kylanpaa L, Moilanen E, Puolakkainen P, Pettila V, et al. Activated protein c does not alleviate the course of systemic inflammation in the APCAP trial. Int J Inflam. 2012;2012:712739.PubMedPubMedCentral Kyhala L, Mentula P, Kylanpaa L, Moilanen E, Puolakkainen P, Pettila V, et al. Activated protein c does not alleviate the course of systemic inflammation in the APCAP trial. Int J Inflam. 2012;2012:712739.PubMedPubMedCentral
121.
go back to reference Malleo G, Mazzon E, Siriwardena AK, Cuzzocrea S. Role of tumor necrosis factor-alpha in acute pancreatitis: from biological basis to clinical evidence. Shock. 2007;28(2):130–40.PubMed Malleo G, Mazzon E, Siriwardena AK, Cuzzocrea S. Role of tumor necrosis factor-alpha in acute pancreatitis: from biological basis to clinical evidence. Shock. 2007;28(2):130–40.PubMed
122.
123.
go back to reference Pooran N, Indaram A, Singh P, Bank S. Cytokines (IL-6, IL-8, TNF): early and reliable predictors of severe acute pancreatitis. J Clin Gastroenterol. 2003;37(3):263–6.PubMed Pooran N, Indaram A, Singh P, Bank S. Cytokines (IL-6, IL-8, TNF): early and reliable predictors of severe acute pancreatitis. J Clin Gastroenterol. 2003;37(3):263–6.PubMed
124.
go back to reference Hughes CB, Grewal HP, Gaber LW, Kotb M, El-din AB, Mann L, et al. Anti-TNFalpha therapy improves survival and ameliorates the pathophysiologic sequelae in acute pancreatitis in the rat. Am J Surg. 1996;171(2):274–80.PubMed Hughes CB, Grewal HP, Gaber LW, Kotb M, El-din AB, Mann L, et al. Anti-TNFalpha therapy improves survival and ameliorates the pathophysiologic sequelae in acute pancreatitis in the rat. Am J Surg. 1996;171(2):274–80.PubMed
125.
go back to reference Oruc N, Ozutemiz AO, Yukselen V, Nart D, Celik HA, Yuce G, et al. Infliximab: a new therapeutic agent in acute pancreatitis? Pancreas. 2004;28(1):e1–8.PubMed Oruc N, Ozutemiz AO, Yukselen V, Nart D, Celik HA, Yuce G, et al. Infliximab: a new therapeutic agent in acute pancreatitis? Pancreas. 2004;28(1):e1–8.PubMed
126.
go back to reference Grewal HP, Mohey el Din A, Gaber L, Kotb M, Gaber AO. Amelioration of the physiologic and biochemical changes of acute pancreatitis using an anti-TNF-alpha polyclonal antibody. Am J Surg. 1994;167(1):214–8. discussion 218–219.PubMed Grewal HP, Mohey el Din A, Gaber L, Kotb M, Gaber AO. Amelioration of the physiologic and biochemical changes of acute pancreatitis using an anti-TNF-alpha polyclonal antibody. Am J Surg. 1994;167(1):214–8. discussion 218–219.PubMed
127.
go back to reference Tekin SO, Teksoz S, Terzioglu D, Arikan AE, Ozcevik H, Uslu E. Use of infliximab in treatment of acute pancreatitis. Bratisl Lek Listy. 2015;116(3):167–72.PubMed Tekin SO, Teksoz S, Terzioglu D, Arikan AE, Ozcevik H, Uslu E. Use of infliximab in treatment of acute pancreatitis. Bratisl Lek Listy. 2015;116(3):167–72.PubMed
128.
go back to reference de Campos T, Deree J, Martins JO, Loomis WH, Shenvi E, Putnam JG, et al. Pentoxifylline attenuates pulmonary inflammation and neutrophil activation in experimental acute pancreatitis. Pancreas. 2008;37(1):42–9.PubMed de Campos T, Deree J, Martins JO, Loomis WH, Shenvi E, Putnam JG, et al. Pentoxifylline attenuates pulmonary inflammation and neutrophil activation in experimental acute pancreatitis. Pancreas. 2008;37(1):42–9.PubMed
129.
go back to reference Abdin AA, El-Hamid MA, El-Seoud SH, Balaha MF. Effect of pentoxifylline and/or alpha lipoic acid on experimentally induced acute pancreatitis. Eur J Pharmacol. 2010;643(2–3):289–96.PubMed Abdin AA, El-Hamid MA, El-Seoud SH, Balaha MF. Effect of pentoxifylline and/or alpha lipoic acid on experimentally induced acute pancreatitis. Eur J Pharmacol. 2010;643(2–3):289–96.PubMed
130.
go back to reference Hughes CB, Gaber LW, Mohey el-Din AB, Grewal HP, Kotb M, Mann L, et al. Inhibition of TNF alpha improves survival in an experimental model of acute pancreatitis. Am Surg. 1996;62(1):8–13.PubMed Hughes CB, Gaber LW, Mohey el-Din AB, Grewal HP, Kotb M, Mann L, et al. Inhibition of TNF alpha improves survival in an experimental model of acute pancreatitis. Am Surg. 1996;62(1):8–13.PubMed
131.
go back to reference Pereda J, Sabater L, Cassinello N, Gomez-Cambronero L, Closa D, Folch-Puy E, et al. Effect of simultaneous inhibition of TNF-alpha production and xanthine oxidase in experimental acute pancreatitis: the role of mitogen activated protein kinases. Ann Surg. 2004;240(1):108–16.PubMedPubMedCentral Pereda J, Sabater L, Cassinello N, Gomez-Cambronero L, Closa D, Folch-Puy E, et al. Effect of simultaneous inhibition of TNF-alpha production and xanthine oxidase in experimental acute pancreatitis: the role of mitogen activated protein kinases. Ann Surg. 2004;240(1):108–16.PubMedPubMedCentral
Metadata
Title
Drug Therapy for Acute Pancreatitis
Authors
Yan Bi, MD, PhD
Tegpal Atwal, MD
Santhi Swaroop Vege, MD
Publication date
01-09-2015
Publisher
Springer US
Published in
Current Treatment Options in Gastroenterology / Issue 3/2015
Print ISSN: 1092-8472
Electronic ISSN: 1534-309X
DOI
https://doi.org/10.1007/s11938-015-0058-7

Other articles of this Issue 3/2015

Current Treatment Options in Gastroenterology 3/2015 Go to the issue

Geriatrics (S Katz, Section Editor)

Anaemia in the Elderly IBD Patient

Pancreas (T Stevens, Section Editor)

Chronic Pancreatitis and Diabetes Mellitus

Pancreas (T Stevens, Section Editor)

Diagnosis of Exocrine Pancreatic Insufficiency

Geriatrics (S Katz, Section Editor)

Management of IBD in the Elderly Patient With Cancer

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine